Literature DB >> 324687

Protein binding of coumarin anticoagulants in disease states.

K Bachmann, R Shapiro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 324687     DOI： 10.2165/00003088-197702020-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  80 in total

1.  Effect of temperature on binding of warfarin by human serum albumin.

Authors:  Y T Oester; S Keresztes-Nagy; R F Mais; J Becktel; J F Zaroslinski
Journal:  J Pharm Sci       Date:  1976-11       Impact factor: 3.534

2.  Protein binding of phenprocoumon in the absence and presence of furosemide.

Authors:  L Foged; S Husted; F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-09

Review 3.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

Review 4.  Effect of disease states on plasma protein binding of drugs.

Authors:  M M Reidenberg
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

Review 5.  Albumin synthesis (second of two parts).

Authors:  M A Rothschild; M Oratz; S S Schreiber
Journal:  N Engl J Med       Date:  1972-04-13       Impact factor: 91.245

6.  Influence of free fatty acid concentration on drug binding to plasma albumin.

Authors:  A A Spector; E C Santos; J D Ashbrook; J E Fletcher
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

7.  Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man.

Authors:  D S Hewick; J McEwen
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

8.  [The reciprocal actions of phenprocoumon (Marcumar) with human serum albumin, erythrocytes and blood].

Authors:  R Niedner; U von Oettingen; F Meyer
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-12

9.  The effects of dextrothyroxine on the kinetics of prothrombin activity: proposed mechanism of the potentiation of warfarin by D-thyroxine.

Authors:  M Weintraub; R T Breckenridge; P F Griner
Journal:  J Lab Clin Med       Date:  1973-02

10.  Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin.

Authors:  R L Williams; W L Schary; T F Blaschke; P J Meffin; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875
View more
  6 in total

1.  Evaluation of the effects of ontogenetic or maturation functions and chronic heart failure on the model analysis for the dose-response relationship of warfarin in Japanese children.

Authors:  Rika Tamura; Nao Watanabe; Saki Nakamura; Naoki Yoshimura; Sayaka Ozawa; Keiichi Hirono; Fukiko Ichida; Masato Taguchi
Journal:  Eur J Clin Pharmacol       Date:  2019-03-08       Impact factor: 2.953

2.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

3.  Aminoglutethimide and warfarin. A new important drug interaction.

Authors:  P E Lønning; S Kvinnsland; G Jahren
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Altered plasma protein binding of drugs in thyroid disease.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of oral anticoagulants.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

Review 6.  Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.

Authors:  H G Shetty; A G Fennerty; P A Routledge
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.